Brought to you by 
SkyePharma and Novartis develop asthma and COPD treatment
18 Feb 2015
Executive Summary
SkyePharma PLC will apply its SkyeHaler and SkyeProtect drug delivery technologies to Novartis's long-acting bronchodilator QAB149 to develop a new product for asthma and chronic obstructive pulmonary disease (COPD).
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SkyePharma and Novartis develop asthma and COPD treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice